A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
This study is testing a new, 'off-the-shelf' cell therapy called FT825 to see if it can help fight advanced solid tumors. It is a Phase 1 trial, meaning the main goal is to figure out the right dose and ensure the treatment is safe for patients.
This trial is for adults with advanced cancer that has not responded to or cannot be cured by standard treatments. You must be active enough to manage daily tasks and meet specific health requirements regarding your heart, liver, and kidneys.
Participants will receive a combination of chemotherapy to prepare the body, followed by the experimental FT825 treatment. The medical team will closely monitor your health and use scans to see how the treatment affects your tumor.
The study is currently recruiting patients at medical centers in Arizona, California, and Connecticut. Please reach out to your oncology team to see if one of these locations is accessible to you.
- 1This is an early-stage study primarily focused on safety.
- 2The therapy uses engineered cells designed to target cancer cells.
- 3Participants must be able to commit to the study protocol and use birth control.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.